文献速递流行病学与生物统计基础与转化研究

生存结局与预测性生物标志物错分类校正的两阶段分层设计

Two-stage stratified designs with survival outcomes and adjustment for misclassification in predictive biomarkers.
PubMed 文献 · Stat Med · 2024-02-26

针对生物标志物分层临床试验中检测或分类规则不完美导致的错分类问题,本文提出一种带错分类校正的两阶段分层设计,用于生存结局分析。利用观察到的生物标志物状态分层信息构建校正log-rank统计量,并据此开发全局与分项假设的序贯检验,通过校正统计量在设计阶段内和阶段间的相关性控制I类错误率并讨论功效分析。方法以非小细胞肺癌免疫治疗的成功开发为例进行说明。

要点

  • 提出两阶段分层设计,对预测性生物标志物错分类进行校正,用于生存结局评估。
  • 利用观察到的生物标志物状态分层构建校正log-rank统计量,用于全局与分项假设的序贯检验。
  • 通过校正统计量在设计阶段内和阶段间的相关性控制I类错误率,并讨论功效分析。

核心结论

  • 所提出的校正log-rank统计量及序贯检验可用于带生物标志物错分类的两阶段分层设计,以评估预测性生物标志物的临床效用。

研究设计与样本

  • 方法学研究,提出针对生存结局的两阶段分层设计,并对预测性生物标志物的错分类进行校正。

主要发现

  • 利用观察到的生物标志物状态分层信息构建校正log-rank统计量,用于真实生物标志物状态分层的检验。
  • 校正log-rank统计量用于开发全局(复合)假设和分项假设的序贯检验。
  • 利用校正log-rank统计量在设计阶段内和阶段间的相关性,在控制I类错误率下进行功效分析。
  • 方法以非小细胞肺癌免疫治疗近期成功开发的例子进行说明。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Biomarker stratified clinical trial designs are versatile tools to assess biomarker clinical utility and address its relationship with clinical endpoints. Due to imperfect assays and/or classification rules, biomarker status is prone to errors. To account for biomarker misclassification, we consider a two-stage stratified design for survival outcomes with an adjustment for misclassification in predictive biomarkers. Compared to continuous and/or binary outcomes, the test statistics for survival outcomes with an adjustment for biomarker misclassification is much more complicated and needs to take special care. We propose to use the information from the observed biomarker status strata to construct adjusted log-rank statistics for true biomarker status strata. These adjusted log-rank statistics are then used to develop sequential tests for the global (composite) hypothesis and component-wise hypothesis. We discuss the power analysis with the control of the type-I error rate by using the correlations between the adjusted log-rank statistics within and between the design stages. Our method is illustrated with examples of the recent successful development of immunotherapy in nonsmall-cell lung cancer.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Chen Y, Lin Y, Lu SE, et al. Two-stage stratified designs with survival outcomes and adjustment for misclassification in predictive biomarkers. Stat Med. 2024. PMID: 38634277. doi:10.1002/sim.10048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。